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Abstract
Background: Recent studies have implicated microglia—the resident immune cells of the brain—in the
pathophysiology of alcoholism. Indeed, post-mortem alcoholic brains show increased microglial markers and
increased immune gene expression; however, the effects of ethanol on microglial functioning and how this impacts
the brain remain unclear. In this present study, we investigate the effects of acute binge ethanol on microglia and
how microglial depletion changes the brain neuroimmune response to acute binge ethanol withdrawal.
Methods: C57BL/6J mice were treated intragastrically with acute binge ethanol for time course and dose-response
studies. Cultured mouse BV2 microglia-like cells were treated with ethanol in vitro for time course studies. Mice were
also administered the colony stimulating factor 1 receptor (CSF1R) inhibitor PLX5622 to deplete microglia from the
brain. These mice were subsequently treated with acute binge ethanol and sacrificed during withdrawal. Brain and BV2
mRNA were isolated and assessed using RT-PCR to examine expression of microglial and neuroimmune genes.
Results: Acute binge ethanol biphasically changed microglial (e.g., Iba1, CD68) gene expression, with initial decreases
during intoxication and subsequent increases during withdrawal. Acute ethanol withdrawal dose dependently increased
neuroimmune gene (e.g., TNFα, Ccl2, IL-1ra, IL-4) expression beginning at high doses. BV2 cells showed biphasic changes
in pro-inflammatory (e.g., TNFα, Ccl2) gene expression following ethanol treatment in vitro. Administration of PLX5622
depleted microglia from the brains of mice. Although some neuroimmune genes were reduced by microglial depletion,
many others were unchanged. Microglial depletion blunted pro-inflammatory (e.g., TNFα, Ccl2) gene expression and
enhanced anti-inflammatory (e.g., IL-1ra, IL-4) gene expression during acute binge ethanol withdrawal.
Conclusions: These studies find acute binge ethanol withdrawal increases microglial and neuroimmune gene expression.
Ethanol exposure also increases microglial pro-inflammatory gene expression in vitro. Furthermore, microglial depletion
decreases expression of microglia-specific genes but has little effect on expression of many other neuroimmune signaling
genes. Microglial depletion blunted the acute binge ethanol withdrawal induction of pro-inflammatory genes and
enhanced induction of anti-inflammatory genes. These findings indicate microglia impact the brain response to acute
binge ethanol withdrawal.
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Background
Alcohol use disorders (AUDs) are a common mental
health disease in which individuals drink excessive
amounts of alcohol despite negative consequences. Many
individuals with AUDs engage in heavy patterns of alcohol
consumption known as binge drinking, defined as drink-
ing to a blood alcohol concentration (BAC) greater than
80 mg/dL [1]. However, many studies in humans have
documented even more extreme binge drinking leading to
BACs around 400 mg/dL [2–4]. Excessive alcohol con-
sumption has several detrimental effects on the brain,
contributing to neurodegeneration [5], neuronal dysfunc-
tion [6], and various other pathologies. Research even sug-
gests excessive alcohol changes the brain to promote
further alcohol consumption [7]. However, much remains
unknown regarding the mechanisms by which excessive
alcohol use negatively impacts the brain.
Interestingly, recent studies have implicated the innate
immune system in the pathophysiology of alcohol use
disorders. Deletion of innate immune genes such as IL1rn
or IL6 decreases voluntary alcohol consumption [8, 9].
Furthermore, alcohol treatment increases innate immune
gene expression in the brain [10, 11]. Even a single, heavy
dose of alcohol increases expression of innate immune
genes such as TNFα and Ccl2 in the brain [12]. Microglia
are the resident innate immune cells of the brain and
thought to be the primary mediators of the brain immune
response to alcohol. Indeed, microglial markers such as
Iba1 are increased in the brains of post-mortem alcoholics
[13, 14], consistent with microglial activation. However,
there are multiple types of microglial activation [15], with
functional effects ranging from pro-inflammatory and
destructive to anti-inflammatory and healing, and in-
creased markers such as Iba1 do not indicate activation
type [16, 17]. While a few studies have begun to investi-
gate the effects of alcohol on microglial function in vivo
[18], much remains unknown. In vitro studies in human
monocytes suggest ethanol may have complex, dynamic
effects, as short-term ethanol exposure decreases inflam-
matory signaling, while long-term ethanol exposure in-
creases inflammatory signaling [19]. Even the microglial
response to a single episode of ethanol exposure and
withdrawal in vivo is not fully understood. Therefore, in
this study, we sought to investigate the dynamic effects of
acute binge ethanol on microglia in vivo.
Understanding the effects of ethanol on microglia is
critical, as microglia interact extensively with other cell
types of the brain to impact brain function. Microglia can
alter synapse formation through brain-derived neuro-
trophic factor (BDNF) [20], synapse elimination through
complement-dependent phagocytosis [21], and synaptic
plasticity through release of cytokines such as TNFα [22].
Furthermore, microglia can either promote or inhibit
neurogenesis depending on their activation state [23, 24].
Activated microglia can also protect against neuronal cell
death [25] or contribute to neuronal cell death [26, 27]
depending on whether they are activated to a trophic or
inflammatory activation state. Indeed, ethanol-induced
changes in microglia may have an important impact on
brain functioning and ultimately behavior. Interestingly, re-
cent research has identified a new pharmacological tool for
studying the role of microglia in vivo. Inhibitors of the col-
ony stimulating factor 1 receptor (CSF1R) deplete microglia
from the brain without known detrimental effects or behav-
ioral changes [28]. This allows for an opportunity to exam-
ine the function of microglia in vivo in a novel way. We
sought to utilize this method to investigate the effects of
microglial depletion on both the normal brain and the
ethanol-treated brain. Furthermore, microglial depletion al-
lows for examination of the contributions of non-microglial
cells to the brain response to ethanol. We examined the ef-
fect of acute binge ethanol and microglial depletion on brain
expression of microglial genes, pro-inflammatory genes,
anti-inflammatory genes, and various other genes including
Toll-like receptors and death receptors. We hypothesized
that acute binge ethanol would cause time and dose-
dependent changes in microglial and neuroimmune gene
expression and that microglial depletion would alter brain
neuroimmune gene expression. We further hypothesized
that microglial depletion would alter the brain neuroim-
mune response to acute binge ethanol withdrawal.
Methods
Animals
Male C57BL/6J mice were ordered from the Jackson
Laboratory and housed in an animal facility at the University
of North Carolina at Chapel Hill. All mice were group
housed (n= 3–4) in a temperature- (20 °C) and humidity-
controlled vivarium on a 12-h/12-h light/dark cycle (light
onset at 0700 h) and provided ad libitum access to food and
water. Experimental procedures were approved by the
Institutional Animal Care and Use Committee of the
University of North Carolina at Chapel Hill and conducted
in accordance with National Institutes of Health regulations
for the care and use of animals. For an overview of all ani-
mal experiments, see Additional file 1: Figure S1.
Mouse time course and dose-response experiments
For the time course experiment, 12-week-old mice were
gavaged with either ethanol (6 g/kg, 25% v/v) or a compar-
able volume of water and sacrificed 6, 12, 18, 24, or 48 h
later. A group of non-gavaged “0 h” mice was included as a
control. All mice were sacrificed mid-morning (9–10 AM).
A parallel group of mice was gavaged with ethanol (6 g/kg,
25% v/v), and tail blood was collected at 1, 6, 12, and 18 h
for the determination of blood alcohol concentrations
(BACs). For the dose-response experiment, 12-week-old
mice were gavaged with ethanol (3, 4.5, or 6 g/kg, 25% v/v)
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or a comparable volume of water and sacrificed 18 h later.
Tail blood was collected at 1 h for the determination of
BACs. All mice were sacrificed mid-morning (9–10 AM).
BACs were determined using a GL5 Analyzer (Analox;
London, UK).
Cell culture time course experiment
The BV2-immortalized mouse microglial cell line was
maintained in DMEM supplemented with 10% FBS, 2 mM
of L-alanyl-L-glutamine dipeptide (GlutaMAX, Thermo-
Fisher, 35050061), 100 units/mL of penicillin, 100 μg/mL of
streptomycin, and 0.25 μg/mL of amphotericin B
(Antibiotic-Antimycotic 100×, ThermoFisher, 15240062).
Cells were maintained in a humidified incubator with 5%
CO2. For time course experiments, BV2 cells were plated at
a density of 1.5 × 105 cells/well in 6-well plates. After
plating, cells were allowed a few hours to adhere and media
was replaced with DMEM supplemented with 2% FBS,
2 mM of L-alanyl-L-glutamine dipeptide, 100 units/mL of
penicillin, 100 μg/mL of streptomycin, and 0.25 μg/mL of
amphotericin B. The cells were then allowed to incubate
overnight. The next day, cells were treated with PBS or
85 mM ethanol in PBS at noon (24-hr time point), 6 PM
(18-hr time point), midnight (12-hr time point), 6 AM the
next day (6-hr time point), or 10:30 AM the next day (1.5-
hr time point). At noon the next day, media were collected
for analysis of ethanol concentrations and TRI reagent was
added to the cells. Total mRNA was extracted as described
below. For evaporation experiments, cells were placed in
the incubator without vaporized ethanol in the chamber,
thereby allowing media ethanol to evaporate over time. For
continuous ethanol exposure experiments, cells were placed
in the incubator with vaporized ethanol to keep media
ethanol concentrations constant. Ethanol was vaporized
into the incubator by placing a beaker with 200 mL of 4%
ethanol into the chamber.
Microglial depletion experiment
The CSF1R inhibitor PLX5622 was provided by Plexxikon
Inc. (Berkeley, CA) formulated at a dose of 1200 mg/kg in
AIN-76A chow by Research Diets (New Brunswick, NJ).
Control chow was also provided. Twelve-week-old mice re-
ceived either PLX5622 chow or control chow for 3 weeks.
Mice (average weight 27 g; range 23–30 g) were then acutely
gavaged with ethanol (6 g/kg, 25% v/v, i.g.) or an equivalent
volume of water and sacrificed 18 h later (at 15 weeks of
age). All mice were sacrificed mid-morning (9–10 AM).
mRNA isolation, reverse transcription, and RT-PCR
Total mRNA was extracted from frozen half-brains by
homogenization in TRI reagent (Sigma-Aldrich, St. Louis,
MO, Cat. # T9424) following the single-step method [29].
Total mRNA was reverse transcribed. Primers used for RT-
PCR are listed in Table 1. In all experiments, 18S rRNA
was used as a reference gene. SYBR Green PCR Master
Mix (Life Technologies, Carlsbad, CA, Cat. # 4367659) was
used for the RT-PCR. The real-time PCR was run with an
initial activation for 10 min at 95 °C, followed by 40 cycles
of denaturation (95 °C, 15 s), annealing/extension (57–58 °
C, 1 min), and finally a melt curve. The threshold cycle
(CT) of each target product was determined and the ΔΔCT
method was used to calculate the percent change compared
to the control group.
Protein isolation and ELISAs
Total protein was extracted from frozen half-brains by
homogenization in cold lysis buffer (20 mM Tris, 0.25 M
sucrose, 2 mM EDTA, 10 mM EGTA, 1% Triton X-100
plus 1 tablet of Complete ULTRA protease inhibitor cock-
tail [Sigma, St. Louis, MO] per 10 mL solution). Homoge-
nates were centrifuged at 100,000g for 40 min, supernatant
was collected, and protein levels determined using the BCA
protein assay reagent kit (PIERCE, Milwaukee, WI). Levels
of TNFα, Ccl2, IL-1ra, and IL-4 were measured using
commercial enzyme-linked immunosorbent assay (ELISA)
kits from R&D Systems (Minneapolis, MN), as per the
manufacturer’s instructions.
Perfusion and brain tissue preparation
Mice were anesthetized with sodium pentobarbital (100 mg/
kg, i.p.) and transcardially perfused with 0.1 M phosphate-
buffered saline (PBS, pH 7.4). The brains used for RT-PCR
or ELISAs were extracted and immediately frozen in liquid
nitrogen. The brains used for immunohistochemistry were
perfused with 4.0% paraformaldehyde in PBS, extracted,
post-fixed in 4.0% paraformaldehyde/PBS solution over-
night, and then placed in a 30% sucrose solution in PBS for
a few days. Brain tissue was sectioned coronally at a thick-
ness of 40 μm on a sliding microtome (MICROM HM450;
ThermoScientific, Austin, TX). Sections were sequentially
collected into well plates and stored at −20 °C in a cryopro-
tectant solution consisting of 30% glycol/30% ethylene glycol
in PBS for immunohistochemistry.
Immunohistochemistry
Free-floating sections were washed in 0.1 M PBS, incubated
in 0.3% H2O2 for 30 min, washed again in PBS, and blocked
for 1 h at room temperature in 0.25% Triton-X100/5%
normal serum (MP Biomedicals, Solon, OH, Cat. #
19135680). Sections were transferred directly from the
block to primary antibody (rabbit anti-Iba1, WAKO, Japan)
diluted in blocking solution and were incubated overnight
at 4 °C. Sections were then washed in PBS, incubated for
1 h in biotinylated secondary antibody (1:200; Vector
Laboratories, Burlingame, CA), and washed and incubated
for 1 h in avidin–biotin complex solution (Vectastain ABC
Kit, Vector Laboratories, Burlingame, CA, Cat. # PK6100).
The chromogen, nickel-enhanced diaminobenzidine (Sigma-
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Table 1 List of primer sequences used in this study
18S F: 5'-GGTAACCCGTTGAACCCCAT
18S R: 5'-CAACGCAAGCTTATGACCCG
Iba1 F: 5'-GGATTTGCAGGGAGGAAAAG
Iba1 R: 5'-TGGGATCATCGAGGAATTG
CD68 F: 5'-TGTCTGATCTTGCTAGGACCG
CD68 R: 5'-GAGAGTAACGGCCTTTTTGTGA
TNFα F: 5'-GACCCTCACACTCAGATCATCTTCT
TNFα R: 5'-CCTCCACTTGGTGGTTTGCT
Ccl2 F: 5'-CCAGCCTACTCATTGGGAT
Ccl2 R: 5'-GGGCCTGCTGTTCACAGTT
IL-1ra F: 5'- CTGTTGGCTGGCCTAATCCC
IL-1ra R: 5'-GCTTTGAACAAGCACCTGCC
IL-4 F: 5'-TGGGTCTCAACCCCCAGCTAGT
IL-4 R: 5'-TGCATGGCGTCCCTTCTCCTGT
IL-10 F: 5'-GCTCTTACTGACTGGCATGAG
IL-10 R: 5'-CGCAGCTCTAGGAGCATGTG
Arg1 F: 5'-TTAGGCCAAGGTGCTTGCTGCC
Arg1 R: 5'-TACCATGGCCCTGAGGAGGTTC
CD11b F: 5'-GAGGCCCCCAGGACTTTAAC
CD11b R: 5'-CTTCTTGGTGAGCGGGTTCT
CX3CR1 F: 5'-TCTTCACGTTCGGTCTGGTG
CX3CR1 R: 5'- TGCACTGTCCGGTTGTTCAT
CSF1R F: 5'-GTCCACGGCTCATGCTGAT
CSF1R R: 5'-GTGAGTACAGGCTCCCAAGAG
CD86 F: 5'-ACGATGGACCCCAGATGCACCA
CD86 R: 5'-GCGTCTCCACGGAAACAGCA
CD206 F: 5'-TCAGCTATTGGACGCGAGGCA
CD206 R: 5'-TCCGGGTTGCAAGTTGCCGT
CD163 F: 5'-CTCTGAATGACCCCCGAGGA
CD163 R: 5'-CACGGCACTCTTGGTTTGTG
IL-1β F: 5'-CTGGTGTGTGACGTTCCCATTA
IL-1β R: 5'-CCGACAGCACGAGGCTTT
IL-6 F: 5'-GGCCTTCCCTACTTCACAAG
IL-6 R: 5'-ATTTCCACGATTTCCCAGAG
iNOS F: 5'-GCTATGGCCGCTTTGATGTG
iNOS R: 5'-TCGAACTCCAATCTCGGTGC
NOX2 F: 5'-GGGAACTGGGCTGTGAATGA
NOX2 R: 5'-CAGTGCTGACCCAAGGAGTT
TGFβ1 F: 5'-CTCCCGTGGCTTCTAGTGC
TGFβ1 R: 5'-GCCTTAGTTTGGACAGGATCTG
Ym1 F: 5'-ACCCCTGCCTGTGTACTCACCT
Ym1 R: 5'-CACTGAACGGGGCAGGTCCAAA
TLR2 F: 5'-GCAAACGCTGTTCTGCTCAG
TLR2 R: 5'-AGGCGTCTCCCTCTATTGTATT
TLR3 F: 5'-TTGTCTTCTGCACGAACCTG
Table 1 List of primer sequences used in this study (Continued)
TLR3 R: 5'-GGCAACGCAAGGATTTTATT
TLR4 F: 5'-GCCTTTCAGGGAATTAAGCTCC
TLR4 R: 5'-AGATCAACCGATGGACGTGTAA
TLR7 F: 5'-ATGTGGACACGGAAGAGACAA
TLR7 R: 5'-GGTAAGGGTAAGATTGGTGGTG
FasL F: 5'-TTGAAAAGCAAATAGCCAACCC
FasL R: 5'-CACTCCAGAGATCAGAGCGG
FasR F: 5'-GCACCCTGACCCAGAATACC
FasR R: 5'-GTTCCATGTTCACACGAGTC
NeuN F: 5'-AACTTATGGAGCGGTCGTGT
NeuN R: 5'-GGCCGATGGTGTGATGGTAA
MAP2 F: 5'-GAGGAAGCAGCAAGTGGTGA
MAP2 R: 5'-GGGAGGATGGAGGAAGGTCT
DCX F: 5'-GACACCATGTGCTTAGGGCT
DCX R: 5'-ATTTGGGCAGTTTTCCCCCT
GFAP F: 5'-TCCTGGAACAGCAAAACAAG
GFAP R: 5'-CAGCCTCAGGTTGGTTTCAT
S100β F: 5'-CTAGGCATTCCCGTGAGCTG
S100β R: 5'-ATGAGCAACCTCTTCGGGTG
MBP F: 5'-CCCTCACGTTATTGTGGCGA
MBP R: 5'-AGACCTTCCAAAGAGCCCCA
CNP F: 5'-GACATAGTACCCGCAAAGGC
CNP R: 5'-AAGAGCTTGGGCAGGAATGT
Pecam1 F: 5'-GCATCGGCAAAGTGGTCAAG
Pecam1 R: 5'-TTGCTGGGTCATTGGAGGTC
ICAM2 F: 5'-ACTGGCACAGAGGAGATTGTG
ICAM2 R: 5'-AGGCTCCAGCAAGCAAAAGA
CD200 F: 5'-CCGAGAAGCTGGTGTCTAGC
CD200 R: 5'-ACCACTTCCACTTGAGCTGT
CX3CL1 F: 5'- CAACTTCCGAGGCACAGGAT
CX3CL1 R: 5'- CCAAACGGTGGTGGAGATGT
c-Fos F: 5'-TGGCACTAGAGACGGACAGA
c-Fos R: 5'-TTTCAACGCCGACTACGAGG
EGR1 F: 5'-GCGATGGTGGAGACGAGTTA
EGR1 R: 5'-AGAGGTCGGAGGATTGGTCA
c-Jun F: 5'-TGGGCACATCACCACTACAC
c-Jun R: 5'-TGACACTGGGAAGCGTGTTC
Arc F: 5'-CCAAGCCCCAGCTCCAATTA
Arc R: 5'-CCTACACACCCTATGCCAGC
C3 F: 5'-CAGGACGTGAGAGTCGATGG
C3 R: 5'-CTCTGCCTATGCTGCCTTCA
C1qA F: 5'-GAAGGGCGTGAAAGGCAATC
C1qA R: 5'-CAAGCGTCATTGGGTTCTGC
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Aldrich, St. Louis, MO, Cat. # D5637), was used to visualize
immunoreactivity. Tissue was mounted onto slides, dehy-
drated, and coverslipped.
Rotarod behavioral experiments
Rotarod testing was performed as previously described
[30] and consisted of walking on a rotarod apparatus (Ugo
Basile, Italy, Mouse Rota-rod, 47600) set at a fixed speed
of 16 rotations-per-minute (rpm). Each mouse underwent
training one day prior to experimental testing. Training
consisted of the mouse remaining on the rod for three
consecutive trials of 180 s. Mice that did not pass this cri-
terion within 18 trials were not included in subsequent
testing. The next day, mice performed a baseline test to
ensure they could remain on the rotarod for 180 s. Mice
were then injected i.p. with either vehicle or the recom-
binant IL-1ra drug, Kineret (obtained from the pharmacy
at UNC Hospitals) at a dose of either 100 or 300 mg/kg.
Thirty minutes later, mice underwent another rotarod test
to ensure there were no effects of IL-1ra on motor activity.
Mice were then injected i.p. with ethanol (2.0 g/kg, 20% v/
v) and tested on the rotarod at 2, 5, 8, 14, 20, and every
subsequent 10 min until 110 min had passed. The time
the mice remained on the rotarod was recorded.
Rotarod testing was performed on another group of
mice, except that these mice received either control
chow or PLX5622 chow for 1 week prior to testing, a
treatment time previously shown to result in substantial
microglial depletion [31]. These mice were otherwise
trained and tested as described above.
Behavioral assessment of intoxication following different
doses of acute binge ethanol
To determine the level of intoxication in mice receiving the
4.5 or 6.0 g/kg doses of ethanol, behavioral assessments of
movement and pain response were performed each hour
post-gavage, similar to previous studies [32]. For assessing
movement, a complete absence of movement other than
breathing was recorded as “No Activity.” Ataxic movement
of the head or limbs or impaired ambulation was recorded
as “Impaired Activity.” Movement that appeared indistin-
guishable from a sober control mouse was recorded as “Full
Activity.” For pain assessment, each hindpaw was pinched.
A complete absence of a response was recorded as “No re-
sponse.” Slight flinching or movement following any pinch
was recorded as “Weak Response.” Full-paw withdrawal for
any pinch was recorded as “Full Response.”
Statistical analyses
The Statistical Package for the Social Sciences (SPSS;
Chicago, IL) was used for all statistical analyses. Data from
time course experiments was analyzed via ANOVA with
Tukey’s post hoc test for multiple comparisons. The data
from dose-response experiments was analyzed via ANOVA
with Dunnett’s post hoc test compared to controls. Data
from microglial depletion experiments was analyzed using
a two-by-two ANOVA with significant interactions being
further investigated using Tukey’s post hoc test for multiple
comparisons. Comparison of two means was analyzed
using Student’s t- test. All values are reported as mean ±
SEM, and significance was defined at a level of p ≤ 0.05.
Results
Acute binge ethanol biphasically and dose dependently
alters microglial gene expression in vivo
Previous studies have found that chronic ethanol increases
microglial markers in vivo [33], and that acute ethanol has
varying effects over time on human monocytes in vitro
[19]. However, few studies have investigated the effects of
acute ethanol on microglia in vivo. Furthermore, it is un-
clear what dose of ethanol is required to impact microglia
acutely in vivo. We therefore performed time course and
dose-response experiments with acute binge ethanol in
vivo. Mice were treated intragastrically with various doses
of ethanol (3, 4.5, and 6 g/kg), and a time course was done
with the highest dose (6 g/kg). Brain mRNA levels of com-
monly studied microglial markers, Iba1 and CD68, were
assessed. Only high doses of ethanol (i.e., 4.5 and 6 g/kg)
altered Iba1 and CD68 mRNA (Fig. 1). Although these
doses yielded high BACs (≥300 mg/dL), no mice died
(Additional file 2: Figure S2). To assess the level of intoxi-
cation in mice receiving these doses, behavioral assess-
ments of movement and pain response were performed
each hour post-gavage, similar to previous studies [32].
There was a transient decrease in movement and pain re-
sponse while BACs were high, with normal behavior
returning as BACs approached zero (Additional file 2 Fig-
ure S2). For the time course, tail blood was collected at 1,
6, 12, and 18 h post-gavage. BACs were approximately
400 mg/dL at 1 h and decreased to 0 mg/dL by 18 h
(Fig. 1a). Interestingly, a biphasic effect on Iba1 mRNA
levels was observed, with a 50% decrease (p < 0.05) at 6 h,
followed by a 23% increase at 24 h (p < 0.05) (Fig. 1a).
CD68 mRNA showed a similar biphasic response, with a
27% decrease (p < 0.05) at 6 h and a 30% (p < 0.05), 36%
(p < 0.05), and 35% (p < 0.05) increase at 12, 18, and 24 h,
respectively (Fig. 1a). Gavage with water did not change
brain CD68 or Iba1 mRNA over time (Additional file 3:
Figure S3). For the dose-response studies, tail blood was
collected at 1 h post-gavage. Increasing doses of ethanol
caused a proportional increase in BACs at 1 h (Fig. 1b).
Mice were sacrificed 18 h post-gavage, a point at which
time course data showed elevated microglial CD68
mRNA. The 4.5 g/kg dose increased CD68 mRNA 27% (p
< 0.05) but did not change Iba1 mRNA (Fig. 1b). The 6 g/
kg dose increased CD68 mRNA 33% (p < 0.05), while Iba1
mRNA was still decreased by 36% (p < 0.05) at this 18-h
time point (Fig. 1b). These results find that acute binge
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ethanol biphasically changes microglial gene expression in
vivo, with initial decreases during intoxication and later
increases during withdrawal. Furthermore, these changes
only happen at high doses of acute ethanol.
Acute binge ethanol withdrawal dose dependently increases
brain pro-inflammatory cytokine expression in vivo
Increased microglial markers suggest microglial activation
but do not indicate the functional changes occurring in
microglia. Microglia can adopt both pro- and anti-
inflammatory activation states [16, 17]. We therefore
sought to assess changes in pro-inflammatory cytokine
expression following acute binge ethanol. Time course
experiments were performed as described above. We
measured the brain expression of TNFα and Ccl2, key pro-
inflammatory cytokines. TNFα expression decreased by
54% at 6 h post-treatment and increased dramatically dur-
ing withdrawal, peaking at 600% (p < 0.05) at 18 h (Fig. 2a).
Ccl2 showed a similar pattern of expression and increased
during ethanol withdrawal, peaking at 1002% (p < 0.05) at
18 h (Fig. 2b). Gavage with water did not significantly
increase TNFα or Ccl2 mRNA at any time point
(Additional file 4: Figure S4). These marked changes in
mRNA levels were accompanied by increased brain TNFα
and Ccl2 protein levels at 18 h post-gavage. TNFα protein
increased 345%, while Ccl2 increased from less than 1 pg/
mL to approximately 17 pg/mL as determined by ELISAs
(Additional file 5: Figure S5). These results find that acute
binge ethanol withdrawal increases brain TNFα and Ccl2
mRNA and protein during withdrawal, similar to the
microglial markers.
In order to determine the dose of acute binge ethanol
required to impact pro-inflammatory cytokine expression,
we performed in vivo dose-response curves as described
above. The 3 g/kg dose of ethanol did not change TNFα or
Ccl2 at the 18-h time point. The 4.5 g/kg dose of ethanol
increased TNFα 218% (p < 0.05) and Ccl2 236% at 18 h
post-gavage (Fig. 2c, d). TNFα and Ccl2 expression
increased exponentially to 672% (p < 0.05) and 873% (p <
0.05), respectively, with the 6 g/kg dose (Fig. 2c, d). These
results find that acute binge ethanol dose dependently in-
creases brain pro-inflammatory cytokine expression during
withdrawal beginning at high doses.
Acute binge ethanol withdrawal dose dependently increases
brain anti-inflammatory cytokine expression in vivo
Microglia often react to insults in a complex and dynamic
manner consisting of both pro-inflammatory and anti-
inflammatory responses. We therefore assessed changes in
brain anti-inflammatory gene expression following acute
binge ethanol. Mice were treated with acute binge ethanol
as described above. We measured expression of IL-1ra
and IL-4, key anti-inflammatory cytokines. IL-1ra expres-
sion increased modestly to 132% at 24 h after ethanol
treatment (Fig. 3a). Expression of IL-4 peaked at 238% (p
< 0.05) at 12 h and decreased to 174% (p < 0.05) by 24 h
(Fig. 3b). Gavage with water did not significantly increase
IL-1ra or IL-4 mRNA at these time points (Additional file
4: Figure S4). Similar changes in brain IL-1ra and IL-4
protein were observed 18 h post-gavage. While IL-1ra
protein was unchanged, IL-4 protein increased approxi-
mately ninefold as determined by ELISAs (Additional file
5: Figure S5). These results find that acute binge ethanol
increases brain IL-4 mRNA and protein during
withdrawal.
Fig. 1 Acute binge ethanol biphasically and dose dependently changes
microglial gene expression. a Time course of blood alcohol
concentrations and brain microglial mRNA following acute binge
ethanol: Mice were gavaged with ethanol (6 g/kg, 25% v/v) and tail
blood was collected at 1, 6, 12, and 18 h to determine BACs (dashed
line—left axis). Brain mRNA was collected at 0, 6, 12, 18, or 24 h and
microglial Iba1 and CD68 mRNA levels were measured (solid lines—right
axis). Note that Iba1 and CD68 mRNA decreased when BACs were high
and increased when BACs dropped. b Ethanol dose-response curve: Mice
were gavaged with ethanol (3, 4.5, or 6 g/kg, 25% v/v) or water. Tail
blood was collected 1 h post-gavage to assess BACs (dashed line—right
axis). At 18 h post-gavage, brain mRNA was collected and microglial Iba1
and CD68 mRNA levels were measured (light and dark gray bars, left axis).
Ethanol dose dependently altered Iba1 and CD68 mRNA. Data are
presented as mean ± SEM. *p< 0.05 for CD68, †p< 0.05 for
Iba1. n= 5–7/group
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In order to determine the dose of acute binge ethanol re-
quired to impact anti-inflammatory cytokine expression,
we performed in vivo dose-response curves as described
above. The 3 g/kg dose of ethanol did not change IL-1ra or
IL-4 at the 18-h time point. The 4.5 g/kg dose of ethanol
increased IL-1ra 170% (p < 0.05) and IL-4 193% (p < 0.05)
at 18 h post-gavage (Fig. 3c, d). IL-1ra expression de-
creased to 136% with the 6 g/kg dose, while IL-4 expres-
sion increased to 224% (p < 0.05) (Fig. 3c, d). These data
find that acute binge ethanol dose dependently alters brain
anti-inflammatory cytokine expression during withdrawal.
Acute ethanol exposure alters microglial cytokine
expression in vitro
Ethanol-induced changes in neuroimmune gene expression
in vivo could be due to direct actions of ethanol on micro-
glia or due to immune signaling across other brain cell
types, such as endothelial cells, astrocytes, and even neu-
rons [34–36]. To determine whether ethanol exposure and
withdrawal can directly alter microglial gene expression,
cultured BV2 microglia-like cells were treated with ethanol
in vitro. Cells were treated with ethanol, but without vapor-
ized ethanol in the incubation chamber, allowing the etha-
nol to evaporate from the media and simulate the ethanol
clearance that occurs in vivo. Media ethanol concentrations
were measured and BV2 mRNA was collected over time.
Ethanol concentrations decreased from an initial concen-
tration of approximately 400 mg/dL to nearly 0 mg/dL over
24 h (Fig. 4). Gene expression in ethanol-treated BV2 cells
was normalized to gene expression in PBS-treated BV2 cells
at each time point. This was done to normalize gene expres-
sion changes over time (Additional file 6: Figure S6). Ethanol
treatment initially decreased TNFα mRNA 47% (p < 0.05) at
1.5 h post-treatment, but later increased TNFα mRNA to
250% (p < 0.05) of controls 24 h post-treatment (Fig. 4a).
Ccl2 mRNA showed a similar pattern, with an initial de-
crease in expression through 12 h of treatment followed by
a 312% (p < 0.05) increase at 24 h post-treatment (Fig. 4b).
Ethanol also decreased IL-1ra expression 45% (p < 0.05) at
12 h and decreased IL-4 expression 53% (p < 0.05) at 1.5 h
(Fig. 4c, d). To determine whether decreases in BV2 gene
expression were due to cell death, we used the vital stain
Trypan blue to determine cell viability. Results showed no
changes in BV2 viability at multiple time points of post-
ethanol treatment (Additional file 7: Figure S7). To deter-
mine whether increased pro-inflammatory gene expression
was dependent on ethanol evaporation, identical experi-
ments were performed, except ethanol was vaporized into
Fig. 2 Acute binge ethanol withdrawal increases brain pro-inflammatory gene expression. a, b Time course of blood alcohol concentrations and
brain TNFα and Ccl2 mRNA following acute binge ethanol: Mice were gavaged with ethanol (6 g/kg, 25% v/v) and tail blood was collected at 1,
6, 12, and 18 h to determine BACs (dashed line—left axis). Brain mRNA was collected at 0, 6, 12, 18, or 24 h and TNFα mRNA and Ccl2 mRNA were
assessed (solid line—right axis). Note that TNFα and Ccl2 mRNA increased during withdrawal when BACs dropped. c, d Ethanol dose-response
curve: Mice were gavaged with ethanol (3, 4.5, or 6 g/kg, 25% v/v) or water. Tail blood was collected 1 h post-gavage to assess BACs (dashed
line—right axis). At 18 h post-gavage, brain mRNA was collected and TNFα and Ccl2 transcript levels were assessed (gray bars, left axis). Data are
presented as mean ± SEM. *p < 0.05. n = 5–8/group
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the incubator chamber to keep MECs constant (Additional
file 8: Figure S8). After 24 h of continuous ethanol exposure,
BV2 TNFα mRNA was unchanged, while Ccl2 mRNA was
decreased 17% (p < 0.05) (Additional file 8: Figure S8), con-
sistent with ethanol evaporation being required for in-
creased pro-inflammatory gene expression. These results
find that ethanol treatment biphasically alters BV2
microglia-like gene expression in vitro, with increased
pro-inflammatory gene expression occurring after ethanol
clearance, and consistent with ethanol having direct ef-
fects on microglia.
PLX5622 decreases expression of microglial genes and
alters expression of some neuroimmune genes in vivo
To further understand which gene expression changes are
due to microglia, we sought to deplete microglia from the
brain and then administer acute binge ethanol. This would
allow us to assess the contribution of microglial and non-
microglial cells to the brain response to ethanol. Microglial
depletion was performed by administering the CSF1R
inhibitor PLX5622 to C57BL/6J mice for 3 weeks, a duration
previously shown to result in maximal microglial depletion
[28]. We first characterized the effects of PLX5622 treat-
ment on microglial and neuroimmune gene expression. RT-
PCR and immunohistochemistry for the microglial marker
Iba1 found that PLX5622 reduced Iba1 mRNA 94% (p <
0.05) (Fig. 5a) and almost completely eliminated Iba1+ cells
(Fig. 5b), consistent with PLX5622 depleting microglia from
the brain. Expression of several other microglial markers
(CD68, CD11b, CX3CR1, etc.) was reduced by 80% or more
by PLX5622 (p < 0.05) (Fig. 6a), further suggesting substan-
tial microglial depletion. Expression of pro-inflammatory
genes, anti-inflammatory genes, and many other genes was
also assessed. Interestingly, microglial depletion decreased
basal expression of TNFα 32% (p < 0.05) and NOX2 54% (p
< 0.05) (Fig. 6a) but did not decrease basal expression of IL-
1β, IL-6, or iNOS, suggesting these genes may be expressed
in other cell types. PLX5622 decreased expression of TGFβ1
56% (p < 0.05) but did not decrease expression of other
examined anti-inflammatory genes. We also examined
expression of multiple Toll-like receptors (TLRs)—a group
of innate immune receptors. PLX5622 decreased brain
expression of TLR2 36% (p < 0.05) and TLR7 76% (p < 0.05)
but surprisingly did not decrease expression of TLR3 and
TLR4 (Fig. 6a). This suggests these neuroimmune genes
may be expressed in other CNS cell types. Furthermore,
expression of genes encoding death receptors—receptors
that contribute to apoptosis—and death receptor ligands,
such as FasL and FasR, were unchanged with microglial
depletion. These results suggest that PLX5622 depletes
Fig. 3 Acute binge ethanol withdrawal increases brain anti-inflammatory gene expression. a, b Time course of blood alcohol concentrations and
brain IL-1ra and IL-4 mRNA following acute binge ethanol: Mice were gavaged with ethanol (6 g/kg, 25% v/v) and tail blood was collected at 1, 6,
12, and 18 h to determine BACs (dashed line—left axis). Brain mRNA was collected at 0, 6, 12, 18, or 24 h and IL-1ra and IL-4 mRNA were assessed
(solid line—right axis). c, d Ethanol dose-response curve: Mice were gavaged with ethanol (3, 4.5, or 6 g/kg, 25% v/v) or water. Tail blood was
collected 1 h post-gavage to assess BACs (dashed line—right axis). At 18 h post-gavage, brain mRNA was collected and IL-1ra and IL-4 mRNA were
assessed (gray bars, left axis). Data are presented as mean ± SEM. *p < 0.05. n = 5–8/group
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Fig. 5 Treatment with CSF1R inhibitor PLX5622 depletes microglia from the brains of mice. C57BL/6J mice received chow containing 1200 mg/kg
PLX5622 for 3 weeks. a RT-PCR on whole brain mRNA showed a 94% reduction in Iba1 mRNA, indicating substantial depletion of microglia. Data
are represented as mean ± SEM. *p < 0.05, Student’s t test, n = 6/group. b Immunohistochemical staining for Iba1 confirmed depletion of microglia
across the brain. Illustrations show a section of the striatum, hippocampus and midbrain
Fig. 4 Acute ethanol changes BV2 microglial cytokine gene expression in vitro. Time course of cytokine expression in ethanol-treated BV2 cells: Microglia-like
BV2 cells were treated with ethanol (85 mM) and the ethanol evaporated over time. Media ethanol concentrations (MECs) were measured (dashed line—left
axis) and mRNA was collected from the BV2 cells. mRNA levels of a TNFα b Ccl2 c IL-1ra, and d IL-4 in ethanol-treated cells were normalized to mRNA levels
in PBS-treated control cells (solid line—right axis). Data are presented as mean ± SEM. *p< 0.05. n= 4–6/group
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microglia, but does not alter expression of many genes asso-
ciated with neuroimmune signaling.
In order to investigate the specificity of PLX5622 for
microglia and potential effects on other brain cell types,
we assessed the expression of several other genes. Micro-
glial depletion caused no change in expression of the
neuronal marker MAP2 or neuroprogenitor marker DCX.
However, there was a small, but statistically significant in-
crease in expression of neuronal marker NeuN (Fig. 6b)
and a 48% increase in astrocyte marker GFAP (p < 0.05).
There was no effect on astrocytic S100β expression
(Fig. 6b). Oligodendrocyte markers myelin basic protein
(MBP) and 2′,3′-cyclic-nucleotide 3′-phosphodiesterase
(CNP) were not changed by microglial depletion (Fig. 6b).
There was a small, but statistically significant 17% de-
crease in endothelial marker ICAM2, but no change in
endothelial marker Pecam1 (Fig. 6b). We also examined
expression of the neuronal-microglial interaction genes,
CD200 and CX3CL1 (also known as fractalkine). CD200
and CX3CL1 are expressed on neurons and interact with
the CD200 receptor and CX3CR1 located on microglia to
regulate their activity [37]. Interestingly, microglial deple-
tion did not change neuronally expressed CD200 and
CX3CL1 (Fig. 6b), despite microglial CX3CR1 being mark-
edly decreased. Since microglia play a role in synaptic
elimination and synaptic plasticity [38], we also assessed
the expression of C3 and C1qA, complement factors in-
volved in synaptic pruning, as well as four immediate-
early genes (IEGs), genes that are induced following neur-
onal activation. Microglial depletion increased C3 expres-
sion 84% (p < 0.05) and decreased C1qA expression to 1%
(p < 0.05). No significant changes in either c-Fos, EGR1, c-
jun, or Arc were found (Fig. 6b). These results find that
microglial depletion has little effect on basal expression of
several markers of other CNS cell types.
Microglial depletion alters the brain neuroimmune
response to acute binge ethanol withdrawal
To determine the role of microglia in the brain response
to acute binge ethanol withdrawal, microglia were
depleted from the brains of mice as described above.
Microglia-depleted mice were gavaged with ethanol and
brain mRNA was isolated 18 h post-treatment, a time
when expression of microglial and cytokine genes was
maximal. Expression of several genes was assessed via
RT-PCR (Table 2). Microglial depletion completely
blocked ethanol withdrawal-induced TNFα expression
(Fig. 7a), reducing TNFα mRNA from about 600 to
104% (p < 0.05). Microglial depletion partially blocked
ethanol withdrawal-induced Ccl2 expression, decreasing
Fig. 6 Treatment with CSF1R inhibitor PLX5622 alters brain gene expression. Mice received chow containing PLX5622 for 3 weeks and mRNA was
isolated from whole brain. a RT-PCR showed marked reduction in several microglial transcripts, indicating substantial microglial depletion. Other
neuroimmune transcripts were also assessed. b The effects of PLX5622 on non-microglial transcripts were also assessed. Note that PLX5622 had
little to no effect on neuronal, oligodendrocyte, or endothelial transcripts, but increased the astrocyte marker GFAP. Also note the marked
changes in synaptic pruning genes, C3 and C1qA. Data are represented as mean ± SEM. *p < 0.05, Student’s t test, n = 6/group
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Table 2 Effects of acute binge ethanol and/or microglial
depletion on brain gene expression
CON –M E –M+ E
Microglial markers
Iba1a, b, c 100 ± 1A 6 ± 0.4B 68 ± 3C 6 ± 1B
CD11ba, b, c 100 ± 2A 3 ± 1B 57 ± 2C 5 ± 1B
CD45a 100 ± 7 52 ± 7 121 ± 15 69 ± 5
MHCII 100 ± 8 68 ± 22 67 ± 4 48 ± 15
M1 microglial markers
CD68a, b 100 ± 6 17 ± 2 136 ± 9 42 ± 4
CD86a, b, c 100 ± 1A 2 ± 0.3B 127 ± 6C 5 ± 2B
iNOSa, b, c 100 ± 24A 135 ± 37A 170 ± 37A 812 ± 145B
NOX2a 100 ± 13 46 ± 11 137 ± 14 51 ± 10
M2 microglial markers
CD206a 100 ± 2 4 ± 0.2 91 ± 5 5 ± 0.3
CD163a, b 100 ± 7 15 ± 3 127 ± 11 30 ± 3
Arg1a, b 100 ± 8 103 ± 10 108 ± 13 157 ± 11
Ym1 100 ± 15 133 ± 32 194 ± 36 197 ± 57
Pro-inflammatory cytokines
IL-1βb 100 ± 6 95 ± 14 143 ± 17 174 ± 16
TNFαa, b, c 100 ± 8A 68 ± 11A 600 ± 90B 104 ± 26A
IL-6b 100 ± 9 92 ± 6 131 ± 13 164 ± 9
Ccl2b 100 ± 12 127 ± 36 1002 ± 308 355 ± 60
Anti-inflammatory cytokines
IL-10b, c 100 ± 5A 91 ± 7A 112 ± 11A 152 ± 9B
IL-4b, c 100 ± 7A, B 84 ± 5A 186 ± 10B 291 ± 40C
IL-1raa, b 100 ± 5 113 ± 19 117 ± 17 173 ± 16
TGF-β1a 100 ± 3 44 ± 3 107 ± 11 58 ± 8
CNS cell types
NeuNa 100 ± 4 120 ± 5 108 ± 5 125 ± 10
MAP2 100 ± 3 106 ± 4 108 ± 4 102 ± 5
DCXb 100 ± 7 97 ± 7 84 ± 3 83 ± 6
GFAPa 100 ± 5 148 ± 11 111 ± 11 145 ± 10
S100β 100 ± 5 91 ± 5 91 ± 4 95 ± 6
CNP 100 ± 3 93 ± 7 86 ± 2 92 ± 7
MBP 100 ± 9 91 ± 6 84 ± 7 85 ± 5
ICAM2b, c 100 ± 6A 83 ± 5A 108 ± 11A 144 ± 8B
Pecam1 100 ± 3 97 ± 4 103 ± 9 110 ± 7
Toll-like receptors
TLR2a, b 100 ± 4 64 ± 7 133 ± 8 94 ± 7
TLR3 100 ± 8 103 ± 6 99 ± 3 100 ± 5
TLR4b 100 ± 8 82 ± 9 137 ± 11 125 ± 11
TLR7a, b, c 100 ± 5A 24 ± 4B 152 ± 6C 38 ± 3B
Neuron-microglia signaling
CX3CL1a, b, c 100 ± 3A 93 ± 2A 96 ± 4A 75 ± 3B
CX3CR1a 100 ± 5 1 ± 0.1 112 ± 15 4 ± 1
Table 2 Effects of acute binge ethanol and/or microglial
depletion on brain gene expression (Continued)
CD200 100 ± 5 106 ± 5 102 ± 3 104 ± 3
CD200R1 100 ± 16 70 ± 9 105 ± 16 91 ± 8
CSF1 100 ± 2 120 ± 5 113 ± 5 104 ± 5
CSF1Ra 100 ± 5 2 ± 0.3 91 ± 4 4 ± 1
Neurotrophins
BDNFa, c 100 ± 4A, B 101 ± 4A, B 113 ± 6A 86 ± 5B
NGF 100 ± 6 103 ± 3 96 ± 4 107 ± 4
NT3 100 ± 7 111 ± 9 96 ± 6 117 ± 10
NT4/5a, b 100 ± 6 115 ± 15 131 ± 10 176 ± 17
Cytokine receptors
IL-1R1a, b 100 ± 4 113 ± 8 130 ± 6 189 ± 20
TNFR1b 100 ± 2 101 ± 5 131 ± 4 120 ± 6
TNFR2a, b 100 ± 5 55 ± 2 124 ± 5 70 ± 6
CCR2 100 ± 11 110 ± 21 131 ± 22 144 ± 13
Immediate-early genes
c-Fos 100 ± 6 99 ± 13 155 ± 26 123 ± 20
EGR1 100 ± 9 96 ± 4 121 ± 8 92 ± 13
Arc 100 ± 10 81 ± 13 105 ± 17 75 ± 19
c-Junb, c 100 ± 7A, B 81 ± 5A 105 ± 5A, B 116 ± 8B
Apoptosis pathways
FasLa, b, c 100 ± 6A 98 ± 11A 121 ± 8A 186 ± 20B
FasRb 100 ± 3 107 ± 7 146 ± 17 210 ± 25
TL1Ab 100 ± 9 88 ± 8 127 ± 25 157 ± 12
DR3a 100 ± 5 71 ± 7 91 ± 9 55 ± 9
TRAILb 100 ± 5 108 ± 5 88 ± 7 67 ± 13
DR5a 100 ± 6 106 ± 5 91 ± 6 139 ± 17
LTαa, b, c 100 ± 5A 95 ± 10A 120 ± 19A 233 ± 25B
FADD 100 ± 3 98 ± 5 99 ± 4 114 ± 14
Caspase-3 100 ± 4 112 ± 4 112 ± 4 130 ± 12
Clock genes
Per1b 100 ± 3 111 ± 8 155 ± 6 185 ± 41
Per2b, c 100 ± 8A 123 ± 5A, B 202 ± 7C 147 ± 12B
BMAL1 100 ± 5 95 ± 5 104 ± 4 110 ± 6
Neurotransmitter systems
CRFa 100 ± 8 87 ± 7 93 ± 6 73 ± 7
DAT 100 ± 5 98 ± 7 92 ± 4 100 ± 4
GluR1b 100 ± 2 101 ± 4 123 ± 3 121 ± 10
NPY 100 ± 2 95 ± 4 96 ± 4 96 ± 3
Other
Glucocorticoid
Receptor
100 ± 5 99 ± 3 96 ± 3 90 ± 6
HMGB1 100 ± 4 103 ± 7 101 ± 4 109 ± 4
COX2b 100 ± 7 106 ± 5 140 ± 7 151 ± 9
MMP9b 100 ± 2 106 ± 7 125 ± 6 133 ± 8
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Ccl2 mRNA from approximately 1000 to 355% (Fig. 7a).
Interestingly, microglial depletion enhanced the ethanol
withdrawal response of several anti-inflammatory genes.
Withdrawal-induced IL-1ra was increased from 117 to
173% with microglial depletion (Fig. 7b). Microglial
depletion also enhanced the ethanol withdrawal response
of anti-inflammatory cytokines IL-4 and IL-10 to 291% (p
< 0.05) and 151% (p < 0.05), respectively (Fig. 7b). These
results find that microglial depletion blunts the acute
binge ethanol withdrawal pro-inflammatory gene response
and enhances the anti-inflammatory gene response.
Previous studies have implicated microglia in ethanol-
induced neurodegeneration [33]. We therefore sought to
examine whether microglial depletion changed ethanol in-
duction of cell death processes. One mechanism by which
ethanol can induce cell death is through death receptors—a
group of cytokine receptors that play a role in apoptosis.
We therefore examined the role of microglia in ethanol-
induced expression of death receptor genes. Microglial de-
pletion enhanced the ethanol response of brain LTα, TL1A,
and FasL to 233 (p < 0.05), 157, and 186% (p < 0.05) of con-
trol levels, respectively (Table 2). Microglial depletion also
enhanced the ethanol response of FasR to 210% of control
levels (Table 2). These results find that microglial depletion
enhances ethanol withdrawal-induced expression of mul-
tiple death receptor genes.
Microglial depletion does not alter the behavioral
response to acute binge ethanol
Other studies suggest that microglia mediate the behavioral
effects of acute ethanol treatment, specifically ethanol-
induced motor impairment [30]. We therefore sought to
investigate the effects of microglial depletion on ethanol-
induced motor impairment. After 1 week of PLX5622
treatment, a time when microglia are mostly depleted [28],
mice were treated with acute ethanol and tested for motor
impairment on the rotarod as previously described [30].
There was no effect of 1 week of microglial depletion on
motor coordination at any time point after ethanol treat-
ment (Additional file 9: Figure S9). To further test the ef-
fects of microglial/monocyte-associated pro-inflammatory
IL-1β signaling on ethanol-induced motor impairment, we
attempted to replicate a previous study finding that Kineret,
an antagonist of IL-1β signaling, blunted ethanol-induced
motor impairment [30]. Mice were treated with two differ-
ent doses of Kineret, 100 and 300 mg/kg, 30 min before
ethanol treatment and rotarod testing. We did not observe
an effect of either dose of Kineret on ethanol-induced
motor impairment (Additional file 9: Figure S9). This may
be due to our use of C57BL/6 mice, whereas the previous
study used Balb/c mice [30]. Overall, our results do not
support the hypothesis that microglia play a role in the
effects of acute ethanol-induced motor impairment.
Table 2 Effects of acute binge ethanol and/or microglial
depletion on brain gene expression (Continued)
IL-12 100 ± 5 112 ± 7 99 ± 8 101 ± 6
IL-34 100 ± 7 101 ± 6 96 ± 7 262 ± 80
NLRP3a, b 100 ± 3 27 ± 4 159 ± 22 57 ± 6
Nogo 100 ± 4 114 ± 6 124 ± 5 116 ± 3
Values are for mRNA levels set to 100% of controls. Control or microglia-depleted
mice were gavaged with either water or ethanol (6 g/kg, 25% v/v) and sacrificed
18 h post-treatment
A, B, C, D = means with different letters are significantly different (p< 0.05, Tukey’s
post hoc test) from each other. Means with the same letters are not significantly
different from each other. Only means with significant interactions are labeled with
letters. Data represent mean± SEM
CON column represents water-treated control mice, —M, microglia-depleted
mice, E, ethanol-treated mice, —M + E, microglia-depleted and
ethanol-treated mice
aMain effect of microglial depletion
bMain effect of ethanol treatment
cInteraction
Fig. 7 Microglial depletion alters the neuroimmune response to acute
binge ethanol withdrawal. Microglia-depleted mice were gavaged with
either ethanol (6 g/kg, 25% v/v) or water and sacrificed 18 h later. a
Levels of pro-inflammatory TNFα and Ccl2 transcripts were determined
in whole brain mRNA. b Levels of anti-inflammatory IL-1ra, IL-10, IL-4,
and Arg1 were determined in whole brain mRNA. Data are represented
as mean ± SEM. *p < 0.05 Tukey’s post hoc test compared to all other
groups. n = 6–8/group
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Discussion
In this present study, we examined the effects of acute
binge ethanol on microglia and how microglial depletion
changes the brain neuroimmune response to acute binge
ethanol withdrawal. We report that acute binge ethanol
biphasically changes microglial marker gene expression,
with initial decreases during intoxication, followed by later
increases during withdrawal when ethanol was gone
(Fig. 8a; Additional file 10). Acute binge ethanol with-
drawal dose - dependently increased neuroimmune gene
expression, starting at high doses (Additional file 11). Cul-
tured microglia-like cells showed biphasic changes in pro-
inflammatory gene expression with ethanol treatment and
evaporation in vitro, consistent with direct effects on
microglia (Additional file 12). Also, microglial depletion
reduced expression of some neuroimmune genes, while
many others were unchanged, suggesting that neuroim-
mune genes are expressed across many brain cell types
(Fig. 8b). Finally, microglial depletion blunted withdrawal-
induced pro-inflammatory gene expression and enhanced
withdrawal-induced anti-inflammatory gene expression
(Fig. 8c; Table 2). These findings suggest microglia con-
tribute to the impact of heavy binge alcohol on the brain,
particularly during withdrawal.
These studies found that acute ethanol had dose-
dependent effects on microglial and neuroimmune gene
expression in vivo. Acute binge ethanol increased expres-
sion of microglial and neuroimmune genes beginning at
BACs of ~300 mg/dL. To assess the level of intoxication
in mice achieving these BACs, behavioral assessments of
movement and pain response were performed each hour
post-gavage. Behaviorally, these BACs were associated
with transient reductions in movement and pain response,
but no mortality. BACs of this level have also been noted
in humans [2, 4, 39], suggesting these studies model brain
pathology relevant to some human alcoholics. Increasing
the ethanol dose further increased the expression of brain
microglial and neuroimmune genes. This acute binge
ethanol treatment also consistently models microglial and
neuroimmune changes seen with moderate-dose, chronic
ethanol treatment [10, 12]. Indeed, it seems that either
high-dose, acute ethanol or moderate-dose, chronic etha-
nol is required to impact microglial and neuroimmune
gene expression. These results are also consistent with
studies in post-mortem human alcoholic brains that find
increased microglial Iba1 [13, 14]. Overall, these results
find that acute binge ethanol withdrawal dose dependently
increases microglial and neuroimmune gene expression,
with high binge doses required to increase expression
acutely.
We also report that acute binge ethanol has biphasic ef-
fects on microglial gene expression in vivo. Iba1 and CD68
expression initially decreased during intoxication and later
increased during withdrawal. Increased Iba1 during ethanol
withdrawal is consistent with previous chronic ethanol
studies [40]. However, increased CD68 protein was not
observed in previous in vivo studies [18]. Since those
studies report comparably high BACs, differences may be
due to examining protein versus mRNA or due to different
patterns of ethanol treatment. Indeed, the microglial re-
sponse to stimuli can be dynamic and complex [41], and
the response to ethanol likely depends on several factors,
including the dose, pattern of administration, and timing
after ethanol exposure. The use of different species may
also account for the differences between these studies.
Overall, these results show acute binge ethanol has biphasic
effects on microglial gene expression in vivo (Fig. 8a).
These studies also find acute binge ethanol withdrawal
increases both pro-inflammatory and anti-inflammatory
gene expression in the brain. This was accompanied by
increased TNFα, Ccl2, and IL-4 protein. Our results are
consistent with previous studies showing acute ethanol
increased brain TNFα and Ccl2 gene expression in mice
[12]. Our results add to these previous observations by
defining the time course of acute ethanol-induced pro-
inflammatory gene expression. Specifically, it is during
withdrawal that acute binge ethanol increases brain pro-
inflammatory cytokines. These results are also consistent
with studies in rats showing that withdrawal from both
acute and chronic ethanol increases TNFα gene expres-
sion in the brain [42, 43]. While many studies have
focused on the brain pro-inflammatory response to
ethanol [10, 12, 42], only a few studies have examined the
brain anti-inflammatory response to ethanol [18]. These
studies show that IL-4, a key anti-inflammatory cytokine,
is also increased in the brain during withdrawal from
acute binge ethanol. These novel findings show that alco-
hol increases expression of various types of cytokines in
the brain. Increased anti-inflammatory cytokine expres-
sion may represent an additional level of immune dysfunc-
tion with alcohol. Indeed, dysregulated immune systems
often show increases in both pro- and anti-inflammatory
mediators [17]. Overall, these results show induction of
both pro- and anti-inflammatory gene expression in the
brain during acute binge ethanol withdrawal.
Results also showed ethanol had biphasic effects on pro-
inflammatory cytokine expression in microglia-like cells in
vitro, with expression decreased shortly after ethanol
exposure and increased when the ethanol evaporated.
However, expression of anti-inflammatory cytokines only
decreased when ethanol was present and did not increase
at any time point. Changes in gene expression were not
due to BV2 cell death. Furthermore, increased pro-
inflammatory gene expression was dependently on ethanol
evaporation, as continuous ethanol exposure did not in-
crease TNFα or Ccl2 gene expression. These results are
similar to those of other studies finding biphasic effects of
ethanol on human monocytes in vitro. While acute ethanol
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exposure decreases inflammatory signaling [44], chronic
ethanol exposure enhances inflammatory signaling [19].
These data also suggest increased TNFα and Ccl2 gene ex-
pression in vivo reflect direct effects of ethanol withdrawal
on microglia. Indeed, previous studies find that constant
ethanol exposure can act directly on microglia to change
inflammatory signaling [45]. Since ethanol did not increase
BV2 anti-inflammatory gene expression in vitro, this sug-
gests the anti-inflammatory response observed in vivo may
be mediated by other cell types. Indeed, previous studies
have noted that astrocytes provide an anti-inflammatory
balance to the pro-inflammatory activity of microglia [46].
Overall, these data show that ethanol has biphasic effects
on microglial pro-inflammatory gene expression in vitro,
with no increases in anti-inflammatory gene expression.
Treating mice with the CSF1R inhibitor PLX5622 for
3 weeks led to substantial microglial depletion, consistent
with other studies [28, 31]. Indeed, mRNA levels of several
microglial markers were reduced by more than 90%
(Fig. 6a). It is worth noting that mRNA levels of CSF1R
itself were markedly reduced following PLX5622 treat-
ment, suggesting CSF1R is located predominantly on
microglia. Microglial depletion decreased TNFα expres-
sion, consistent with previous studies [28]. However,
mRNA levels of IL-1β, IL-6, Ccl2, and several other im-
mune genes were surprisingly unchanged in PLX5622-
treated mice (Fig. 6a). As the main immune cells of the
CNS, one might expect these genes to be primarily
expressed in microglia and that their expression would
decrease in the microglia-depleted brain. While immuno-
histochemical studies revealed small, scattered popula-
tions of microglia remaining in the brain (Fig. 5), the
extent of depletion was striking. Indeed, whole brain levels
of several microglial marker transcripts were reduced by
Fig. 8 Effects of acute binge ethanol and microglial depletion on brain neuroimmune gene expression. a Acute binge ethanol causes biphasic
changes in microglial gene expression. Various microglial genes such as Iba1 and CD68 decrease during acute intoxication. Later, during
withdrawal, expression of these genes increases. These data suggest the effects of ethanol on microglia depend on time after exposure. b
Microglial depletion alters brain gene expression. Various microglial genes, such as Iba1, decrease with microglial depletion. Other neuroimmune
genes, such as TNFα or TGFβ1, also decrease. However, some neuroimmune genes, such as IL-1β, IL-6, and TLR4, do not decrease, suggesting
these may be predominantly expressed in other cell types. Other genes, such as C3 and GFAP, increase with microglial depletion. c Microglia
mediate a balance between pro- and anti-inflammatory gene expression during acute binge ethanol withdrawal. Microglial depletion blocks
withdrawal-induced pro-inflammatory gene induction (TNFα and Ccl2). However, microglial depletion enhances withdrawal-induced anti-
inflammatory gene induction (IL-1ra and IL-4)
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more than 90% (Fig. 6a). It is possible expression of IL-1β,
IL-6, Ccl2, etc. did not decrease because these genes are
expressed in other brain cell types. Indeed, astrocytes have
been observed to produce IL-1β [47]. Other studies sug-
gest IL-6 is produced by many brain cell types, including
neurons [48, 49], astrocytes [50], and endothelial cells
[51]. Ccl2 expression has also been observed in neurons
[52] and astrocytes [53]. Furthermore, the genes Ym1 and
Arg1 are thought to be microglia-specific markers of the
alternative or M2 activation state. However, some studies
suggest astrocytes may also express Ym1 and Arg1 [54],
and other studies suggest neurons express Arg1 [55].
Studies examining the transcriptome of the brain cell
types also suggest that Arg1 is expressed in neurons [56].
We also examined expression of multiple TLRs. TLRs are
thought to be prominently expressed in microglia [57].
PLX5622 decreased expression of TLR2 and TLR7 but
surprisingly did not significantly decrease TLR3 or TLR4
expression. Indeed, microglial TLR4 is thought to play an
important role in the effects of alcohol on microglia in cell
culture [58]. Data from our studies in this manuscript sug-
gest that TLR3 and TLR4 are expressed in other cell types.
Indeed, TLR3 and TLR4 have been observed to co-localize
with cortical neurons using immunohistochemistry [36,
59]. Furthermore, sequencing studies of the various cell
types of the brain find that TLR3 and TLR4 are promin-
ently expressed in other cell types, including astrocytes
and endothelial cells [56]. Thus, our studies and others
support findings of many genes previously thought to be
microglial specific are likely expressed in other brain cell
types as well. Overall, these results find that PLX5622
treatment decreased expression of many microglial genes
and some, but not all, neuroimmune genes (Fig. 8b).
Expression of certain other genes was also impacted by
microglial depletion. Neuronal markers MAP2 and DCX
were unchanged, while expression of NeuN was slightly in-
creased, consistent with other studies showing little to no ef-
fect of CSF1R inhibitors on neuronal markers [28].
PLX5622 increased the astrocyte marker GFAP and had no
effect on oligodendrocyte markers MBP and CNP, consistent
with previous studies [28]. PLX5622 had no effect on the
endothelial cell markers Pecam1 and ICAM2. Since micro-
glia interact extensively with the other cell types of the CNS,
we also examined expression of some genes that mediate
these interactions. Neurons express CD200 and CX3CL1
(also known as fractalkine). These ligands interact with their
cognate receptors on microglia and function to keep the
microglia in a quiescent state [37]. Interestingly, microglial
depletion did not alter expression of neuronal CD200 or
CX3CL1. Microglia have also been found to play an import-
ant role in synaptic pruning via components of the comple-
ment cascade [60]. Components such as C3 and C1qA “tag”
neural synapses for elimination by microglia. Interestingly,
PLX5622 increased expression of C3 and dramatically
reduced expression of C1qA. It is possible that compensa-
tory upregulation of C3 may be occurring due to a lack of
microglial synaptic elimination. These data also suggest that
C1qA is predominantly expressed in microglia. It is possible
that in the absence of microglia, there may be altered synap-
tic pruning. Finally, since depleting microglia may change
neuronal functioning, we measured the expression of four
immediate-early genes, genes that increase with neuronal
activation. There was no significant difference in ex-
pression of either c-Fos, EGR1, c-jun, or Arc follow-
ing PLX5622 treatment. Overall, these data suggest
that microglial depletion has little effect on markers
of other CNS cell types but markedly alters expres-
sion of synaptic pruning genes.
These studies also examined the role of microglia in the
brain response to acute binge ethanol withdrawal. These
studies are, to our knowledge, the first to do so by deplet-
ing microglia in vivo. Multiple cell types of the CNS ex-
press immune genes [61], leaving it unclear which ethanol
responses are due to microglia. As expected, microglial
depletion reduced expression of multiple microglial genes,
including Iba1, CD68, CD11b, etc. Furthermore, ethanol-
induced TNFα was completely blocked by microglial
depletion, suggesting ethanol-induced TNFα is microglia-
derived. These results are similar to those of other studies
finding microglial depletion completely blocked LPS-
induced TNFα in the brain [28]. Ccl2 mRNA was partially,
but not completely blocked by microglial depletion, sug-
gesting multiple CNS cell types contribute to ethanol-
induced Ccl2 expression. Surprisingly, microglial deple-
tion did not reduce ethanol-induced IL-1β or IL-6. This
finding is unexpected, as one might expect microglia to be
the primary sources of these inflammatory mediators, es-
pecially following an insult. Indeed, microglial depletion
blunted LPS-induced IL-1β in the brain [28]. However,
microglial depletion did not decrease LPS-induced IL-6,
suggesting that other CNS cell types are the primary
sources of IL-6. Microglial depletion also enhanced
withdrawal-induced anti-inflammatory gene expression,
including IL-1ra, IL-4, IL-10, and Arg1. Since small, scat-
tered populations of microglia remain following depletion,
it is possible the remaining microglia contribute to this
immune response. However, it is also possible these genes
are expressed by other brain cell types, such as astrocytes,
during ethanol withdrawal, and microglia normally sup-
press expression of these genes. These results suggest that
microglia play a role mediating the balance of pro- and
anti-inflammatory forces during ethanol withdrawal.
Overall, these results find that microglia play a role in the
neuroimmune effects of ethanol on the brain (Fig. 8c).
This study also examined the effects of microglial deple-
tion on death receptor gene expression following acute
binge ethanol. Interestingly, microglial depletion enhanced
the ethanol response of multiple death receptor/ligand
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genes. Previous studies find that ethanol causes FasR-FasL
induced cell death in the hepatocytes [62]. Furthermore,
ethanol was found to increase FasL mRNA and cell death
in cortical slices in vitro [63]. Since death receptors/li-
gands play important roles in apoptosis, these results indi-
cate that microglial depletion may increase cell death
following acute binge ethanol. While microglia are often
thought to contribute to neurodegeneration [27], there is
literature supporting a role for microglia in neuroprotec-
tion [26]. Indeed, it is likely that microglia can be either
neurotoxic or neuroprotective depending on the circum-
stances. Future studies could further examine the role of
microglia in ethanol-induced cell death. Overall, these re-
sults find that microglial depletion enhances the ethanol
response of death receptor/ligand expression.
Our study also examined the role of microglia in the be-
havioral effects of acute ethanol. This was tested in two
different ways: by using PLX5622 to deplete microglia and
by using the recombinant IL-1ra compound, Kineret,
which is believed to impact microglial function by modu-
lating signaling of the cytokine IL-1β. We specifically used
Kineret in an attempt to replicate previous studies exam-
ining the role of microglia in ethanol-induced motor im-
pairment [30]. We investigated the impact of microglia on
ethanol-induced behavioral changes using the rotarod.
Microglial depletion via 1 week of PLX5622 treatment did
not change ethanol-induced motor impairment at any
time point (Additional file 9: Figure S9). Also, treatment
with two different doses of Kineret (100 and 300 mg/kg)
did not change ethanol-induced motor impairment at any
time point (Additional file 9: Figure S9). These results did
not replicate previous findings that Kineret increased time
spent on the rotarod following ethanol [30]. This may be
due to the fact that different strains of mice were used.
While our study used C57BL/6 mice, the other study used
Balb/c mice [30]. Overall, our results do not support the
hypothesis that microglia mediate the effects of acute
ethanol on motor impairment.
Furthermore, results of this study support acute etha-
nol withdrawal inducing a pro-inflammatory microglial
phenotype. This is supported by the fact that microglia-
like cells treated with ethanol in vitro show a pro-
inflammatory response, but not an anti-inflammatory re-
sponse, and that depleting microglia in vivo blunts the
ethanol-induced pro-inflammatory response. Microglial
activation phenotypes are usually described as occurring
along an M1-M2 spectrum, with M1 representing the
pro-inflammatory, destructive phenotype, and M2 repre-
senting the anti-inflammatory, reparative phenotype.
Previous studies have found varying results regarding
the microglial phenotype induced by ethanol, with some
studies suggesting an M1 phenotype [40] and others
suggesting an M2 phenotype [18]. Microglia have been
shown to exhibit complex, dynamic responses to stimuli
[41]. Therefore, it is likely that the microglial response
to ethanol depends on the species being studied, as well
as the dose, duration, and pattern of alcohol administra-
tion. Indeed, previous studies suggest a single ethanol
binge causes a milder, homeostatic microglial activation
phenotype, while a second binge causes a more robust,
pro-inflammatory phenotype [64]. A complete under-
standing of the effects of ethanol on microglia may require
examining entire microglial transcriptomes. Indeed, recent
studies have called into question the M1-M2 activation
schema, describing instead a complex constellation of
several microglial activation states [15, 65]. Our results also
question various aspects of the M1-M2 scheme, as various
M1-M2 markers, such as iNOS and Arg1, were not re-
duced in microglia-depleted animals. Further studies will
be necessary to define thoroughly the complex effects
of ethanol on microglial function. Such studies will be
critical, as microglia have been found to alter neur-
onal functioning and even behavior [20, 22], and may
contribute to the development or consequences of al-
coholism. Overall, these studies suggest acute ethanol
withdrawal induces pro-inflammatory gene expression
in microglia.
Conclusions
We report in these studies that acute binge ethanol causes
biphasic changes in microglial genes, with an initial de-
crease during intoxication, followed by a later increase
during withdrawal. Also, acute binge ethanol withdrawal
dose dependently increased neuroimmune gene expres-
sion beginning at high doses. Cultured BV2 microglia-like
cells showed biphasic changes in pro-inflammatory gene
expression following ethanol exposure and evaporation in
vitro. Administration of PLX5622 depleted microglia from
the brains of mice. Although some neuroimmune genes
were reduced by microglial depletion, many others were
unchanged, suggesting that the neuroimmune system in-
volves many brain cell types. Finally, microglial depletion
blunted the pro-inflammatory response and enhanced the
anti-inflammatory response to acute binge ethanol with-
drawal. These findings suggest microglia contribute to the
impact of heavy binge ethanol on the brain, particularly
during withdrawal.
Additional files
Additional file 1: Figure S1. Schematic of experimental designs. a) For
the Dose-Response Experiment, mice were gavaged with 3.0, 4.5 or 6.0
g/kg ethanol (25% v/v) and pain response and movement were
qualitatively assessed each following hour. For each group, BACs were
collected 1 hour post-gavage. Mice in these groups were sacrificed at 18
hours and brain mRNA was collected for RT-PCR. Note that mice in the
group receiving 3.0 g/kg ethanol were not qualitatively assessed, as they
exhibited only minor behavioral changes. b) For the Time Course
Experiment, mice were gavaged with 6.0 g/kg ethanol (25% v/v) and
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sacrificed at 6, 12, 18 or 24 hours. A non-gavaged “0 hour” control group
was also included. Brain mRNA was collected for RT-PCR. c) A separate
group of mice was gavaged with 6.0 g/kg ethanol (25% v/v) and tail
blood was collected at 1, 6, 12 and 18 hours for assessment of BACs.
d) Mice were given either Control chow or PLX5622 chow. One week
after starting PLX5622 chow to deplete microglia, mice were injected
intraperitoneally with 2.0 g/kg ethanol (20% v/v) and tested on the
rotarod. After two more weeks of treatment with PLX5622 chow, mice
were gavaged with 6.0 g/kg ethanol (25% v/v) and brain mRNA was
collected 18 hours later for RT-PCR. (TIF 108 kb)
Additional file 2: Figure S2. Behavioral characterization of the acute
binge ethanol model. Mice were gavaged with ethanol (4.5 or 6 g/kg,
25% v/v) and pain response and movement were qualitatively assessed
each following hour. Note that there was 0% mortality, as indicated by
behavior recorded for 100% of mice in each group at each time point. A,
C) For movement, a complete absence of movement other than
breathing was recorded as “No Activity.” Head movement, limb
movement, or impaired ambulation was recorded as “Impaired Activity.”
Movement that was indistinguishable from a control mouse was
recorded as “Full Activity.” B, D) For pain assessment, each hindpaw was
pinched. A complete absence of a response was recorded as “No
response.” Slight flinching or movement following any pinch was
recorded as “Weak Response.” Full-paw withdrawal following any pinch
was recorded as “Full Response.” n = 8/group (TIF 175 kb)
Additional file 3: Figure S3. Acute binge ethanol causes biphasic
changes in brain Iba1 and CD68 mRNA compared to controls. Mice were
gavaged with acute binge ethanol (6 g/kg, 25% v/v) or water and
sacrificed various times post-treatment. A) Brain Iba1 was measured over
time by RT-PCR in both water- and ethanol-treated mice. B) Brain CD68
was measured over time by RT-PCR in both water- and ethanol-treated
mice. Note there is no change in brain Iba1 or CD68 mRNA in water-
treated mice over time. Data are represented as mean ± SEM. *p < 0.05
compared to controls. n = 5–6/group (TIF 1013 kb)
Additional file 4: Figure S4. Acute binge ethanol withdrawal increases
brain TNFα, Ccl2, and IL-4 mRNA compared to controls. Mice were
gavaged with acute binge ethanol (6 g/kg, 25% v/v) or water and
sacrificed various times post-treatment. A) Brain TNFα, B) Ccl2, C) IL-1ra,
and D) IL-4 were measured over time by RT-PCR in both water- and
ethanol-treated mice. Data are represented as mean ± SEM. *p < 0.05
compared to controls. n = 5–7/group (TIF 136 kb)
Additional file 5: Figure S5. Acute binge ethanol increases brain TNFα,
Ccl2, and IL-4 protein during withdrawal. Mice were treated with ethanol
(6 g/kg, 25% v/v) or water and sacrificed 18 h post-treatment. Brain
protein was collected and A) TNFα, B) Ccl2, C) IL-1ra, and D) IL-4 protein
levels were determined via ELISA. Data are represented as mean ± SEM.
*p < 0.05, Student’s t test, n = 6/group (TIF 97 kb)
Additional file 6: Figure S6. Acute ethanol treatment and evaporation
changes BV2 TNFα, Ccl2, IL-1ra, and IL-4 mRNA compared to controls.
Time course of cytokine expression in ethanol-treated and PBS-treated
control BV2 cells: Microglia-like BV2 cells were treated with either ethanol
(85 mM) or PBS and the ethanol was allowed to evaporate away over
time. Transcript levels of A) TNFα B) Ccl2 C) IL-1ra, and D) IL-4 were
assessed in ethanol-treated cells (black dots) and PBS-treated control cells
(white dots). Baseline changes in gene expression likely occur because
the BV2 cells are proliferating and engaging in autocrine-paracrine
signaling in a closed system. Data are represented as mean ± SEM.
*p < 0.05, Student’s t test, n = 4–6/group (TIF 144 kb)
Additional file 7: Figure S7. BV2 viability following ethanol treatment.
Microglia-like BV2 cells were treated with PBS or ethanol (85 mM) and
the ethanol was allowed to evaporate away over time. At 0, 1.5, 12, and
24 h, cell viability was determined with the vital stain, Trypan blue. The
number of live and dead cells was counted, and the number of live cells
was divided by the number of total cells to calculate percent viability.
Note that ethanol treatment did not affect cell viability at any time point.
Data are represented as mean ± SEM. n = 3/group (TIF 514 kb)
Additional file 8: Figure S8. Continuous ethanol treatment does not
increase BV2 TNFα or Ccl2 expression. Microglia-like BV2 cells were
treated with either ethanol (85 mM) or PBS. A) For ethanol-treated cells,
ethanol was vaporized into the incubator to keep media ethanol
concentrations constant. After 24 h of continuous ethanol exposure, BV2
mRNA was isolated and B) TNFα and C) Ccl2 gene expression were
measured. Note that continuous ethanol exposure does not increase BV2
pro-inflammatory cytokine expression at 24 h. Data are represented as
mean ± SEM. *p < 0.05, Student’s t test, n = 6/group (TIF 94 kb)
Additional file 9: Figure S9. The role of microglia in ethanol-induced
motor impairment. Mice were treated with compounds that impact
microglia—either the CSF1R inhibitor PLX5622 or recombinant IL-1ra
(Kineret). A) Mice were fed PLX5622 chow for 1 week to deplete
microglia and injected i.p. with ethanol (2.0 g/kg, 20% v/v). Mice were
then tested on the rotarod at 2, 5, 8, 14, 20 min and every subsequent
10 min post-injection until 110 min had passed. The time the mice
remained on the rotarod was recorded. Note that microglial depletion
with 1 week on PLX5622 chow did not alter the ethanol-induced motor
impairments. B, C) Mice received an intraperitoneal injection of B) 100 or
C) 300 mg/kg IL-1ra 30 min prior to an i.p. injection of ethanol (2.0 g/kg,
20% v/v). Mice were then tested on the rotarod at 2, 5, 8, 14, 20 min and
every subsequent 10 min after ethanol injection until 110 min had
passed. The time the mice remained on the rotarod was recorded. Note
that IL-1ra did not alter the ethanol-induced motor impairments.
n = 8/group (TIF 147 kb)
Additional file 10: Table S1. Effects of acute binge ethanol on brain
gene expression over time (DOC 53 kb)
Additional file 11: Table S2. Effects of acute binge ethanol dose on
brain gene expression during withdrawal (DOC 36 kb)
Additional file 12: Table S3. Effects of ethanol treatment on BV2 gene
expression over time (DOC 47 kb)
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